Research of the Bechthold Group
Research Focus Areas of Our Research Group

The most important scientific goal of our research group is to generate or discover in nature new compounds with antibiotic activity and to develop methods for producing these natural products in quantities of up to 100 mg.
To achieve this goal, we are working on the following projects:

Search for New Actinomycetes in Insects
The insect microbiome has not yet been studied particularly intensively. Nevertheless, it is known that insects are colonized by partly quite specific bacteria. We recently started projects to identify and characterize actinomycetes in insects. The focus is on bees and bark beetles, which we are investigating together with a Freiburg beekeeper and a Freiburg forester.

Awakening “Silent Biosynthetic Gene Clusters” Using Regulatory Genes
Antibiotic biosynthesis genes in actinomycetes are all located close together in a small section of the chromosome. This is referred to as a “biosynthetic gene cluster”.
Of the approximately 30 gene clusters located in an actinomycete genome,
usually only a small number are expressed.
To activate the non-expressed (silent) gene clusters, we investigate the function of regulatory genes in order to use them specifically for cluster activation. Our current investigations focus on c-di-GMP-forming (diguanylate cyclases) and c-di-GMP-degrading (phosphodiesterases) enzymes (see figure).

Fig.: c-di-GMP-forming and c-di-GMP-degrading enzymes
Characterization of Unusual Biosynthetic Enzymes
Enzymes that catalyze unusual reactions are repeatedly found in biosynthetic gene clusters. One example is the enzyme RslO9, which catalyzes a rearrangement during rishirilide biosynthesis (see figure). Elucidating the precise function of these enzymes is the basis for their later use as tools in biotechnology.
Fig.: Baeyer–Villiger oxidation catalyzed by RslO9


Production of New Drugs by “Combinatorial Biosynthesis”
Biosynthetic genes can be used specifically to produce new antibiotics. For many years, we used glycosyltransferase genes to generate new glycosylated drug compounds. We also used self-designed glycosyltransferase genes with altered substrate specificity. We are currently focusing on oxygenase genes, although their potential for “combinatorial biosynthesis” is still being investigated.

Development of a Producer Capable of Producing 24-Desmethylrifamycin in Large Quantities
The antibiotic rifamycin can be used to treat tuberculosis. Unfortunately, in many countries around the world, the causative agents of tuberculosis (Mycobacterium tuberculosis) are resistant to this antibiotic. Prof. Dr. R. Lal from New Delhi developed a strain that produces 24-desmethylrifamycin (Figure 3). This compound can be converted semi-synthetically into derivatives that are also active against resistant pathogens. Unfortunately, the antibiotic is produced only in very small quantities. We are currently trying to modify the strain so that it is able to produce 24-desmethylrifamycin in large quantities.

Fig.: Structure of the antibiotic 24-desmethylrifamycin B